Clinical Trials Logo
  1. Home
  2. Cytomegalovirus (CMV)
  3. NCT05137717

A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Cytomegalovirus (CMV) Clinical Trial

Official title:
A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoietic Stem Cell Transplant (HSCT) or Solid Organ Transplant (SOT)

Clinical Trial Summary

The main aim of the study is to check if treatment with maribavir can protect Japanese people against Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting side effects from it. Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) will take Maribavir tablets two times a day for 8 weeks in this study. During the study, participants will visit their study clinic 18 times as a maximum.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05137717
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date December 23, 2021
Completion date June 27, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05319353 - A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection Phase 3
Completed NCT05571137 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
Not yet recruiting NCT06243731 - A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Not yet recruiting NCT06439342 - A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections Phase 3
Completed NCT05576805 - A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
Not yet recruiting NCT06213974 - A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Completed NCT02775240 - Study of SHP620 (Maribavir) in Healthy Adults Phase 1
Completed NCT01611974 - Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients Phase 2
Completed NCT02931539 - Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Phase 3
Completed NCT02927067 - A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants Phase 3